Market Overview

St. Jude Medical Wins CE Mark of Next-Gen Cardiac Device for Stroke Prevention

Share:
Related STJ
BMO Capital Downgrades St. Jude Medical On 'Less Compelling' Risk/Reward
Benzinga's Top Downgrades
St. Jude Medical declares $0.29 dividend (Seeking Alpha)

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, today announced European CE Mark approval of its AMPLATZER^™ Amulet^™ Left Atrial Appendage Occluder. The Amulet device is used to close the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). According to research, AF leads to an increased risk for stroke. Sealing off the LAA helps prevent the risk of blood clot formation and release, potentially reducing the risk of stroke. The next-generation percutaneous transcatheter device leverages the design and clinical success of the original AMPLATZER^™ Cardiac Plug with additional features allowing treatment of a wider range of appendage anatomies. St. Jude Medical will be showcasing the new AMPLATZER Amulet device during the eighteenth annual Boston AF Symposium at booth 319.

Posted-In: News

 

Related Articles (STJ)

Get Benzinga's Newsletters